Exchange: NASDAQ·Updated 04:10 PM EST
APRE logo

APRE Aprea Therapeutics Inc

$0.4649
$0.0118
(2.60%)
Today
Closed $0.4649
$0.00
(0.00%)
After Hours
Mkt Cap$6.43M
Vol110,559.00

About APRE

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.
62

Bullish Sentiment

How do you feel about APRE?

SNOWBALLDB321
$APRE When Aprea Therapeutics successfully demonstrates that its synthetic lethality pipeline (combining its ATR inhibitor, ATRN-119, and its WEE1 inhibitor, APR-1051) matches the anti-tumor efficacy of AstraZeneca's historical WEE1 program (adavosertib) but without the severe toxicities of adavosertibthe, the stock market reaction will be highly dramatic, resulting in an asymmetrical shift in valuation for Aprea. Historically, AstraZeneca’s adavosertib demonstrated strong efficacy and tumor shrinkage. However, it failed and was discontinued in 2022 because of unacceptable toxicities like severe myelosuppression and GI complications. Delivering the same therapeutic punch without those flaws cracks open a massive market opportunity.
2
SNOWBALLDB321
$APRE This event presentation should move the needle for Aprea. Upcoming Presentation Details Event: 38th EORTC-NCI-AACR Symposium (ENA 2026) Topic: Interim results from the first-in-human Phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Presenting Author: Dr. Timothy A. Yap (MD Anderson Cancer Center) Date and Time: Friday, November 20, 2026, from 3:00 PM to 3:10 PM CET
1
Wolfie_Runs_Alone
$APRE Been a while since there's been movement here. Must be time to grab a few and sit tight.

Advertisement|Remove ads.